initi coverag
expand coverag contract research organ cro industri
expand coverag cro industri initi
compani charl river ia buy icon iclr hold
top pick group
favor expans secular driver
fundament cro industri strong durabl
driver esp healthi capit market dicult forecast therefor
especi intrigu opportun cro expand total
address market non-tradit way self-help angl
abil sell product servic custom base whatev
market environ screen well front
leverag strength core inform busi data
supplier broadli technolog servic clinic research
merger quintil earli sign success includ strong book/bil
clinic busi key custom win technolog servic moreov
compani strength data clinic research tech servic potenti
posit forefront drive toward value-bas care healthcar
continu execut land expand strategi leverag
core strength research model safeti assess discoveri
manufactur servic compani see player
industri plenti room growth alreadi seen valid
strategi recent result convict
compani continu activ deploy capit value-ad acquisit
iclr perform admir exclud largest custom start
see growth acceler strong book said compani
slower deploy capit balanc sheet net cash posit
best day margin expans behind hold-rat lh perform
covanc busi largest cro best describ lumpi though
show strong momentum view total enterpris weigh
challeng clinic lab busi
grow number clinic trial prolifer biotech w/o intern clinic
cro industri expect grow driven increas
 spend biopharma industri increas penetr
drug develop budget expect benet
trend equal trial sponsor increasingli look ration number
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
outsourc vendor trend favor larger player industri
remain fragment see continu opportun value-accret
mind risk heighten trial complex drag project disrupt alway
trend toward increas clinic trial complex larg driven swell
oncolog pipelin pressur backlog convers rate project
disrupt cancel alway risk though less pronounc
prior year mani much higher level custom concentr
spate larg pharma could similarli disrupt
servic provid though risk similarli mitig scale
divers today
fundrais record
improv review time fda contribut increas
number biopharma activ develop pipelin
biopharma partnerships/licens deal
opportun outsourcing/cro penetr
 spend larg molecul expect
sector consolid
rose grow number trial heighten complex
cro industri larg fragment domin
overview cro outsourc arrang
clinic trial futur
expect greater integr real world data make tria
debat drive synergi expand asset base
figur cro framework ordin rank stock
framework select stock multifacet
select stock use number consider foremost among
evalu whether see upsid number and/or upsid investor
sentiment capit deploy opportun multipl expans likelihood
compani candid also import consider
investor rank stock coverag attribut
upsid numbersupsid sentimentcapit allocationtargetmultipl expansionratingiqvbuycrlbuylhholdiclrholdmor favor decemb
fundrais record high
robust capit market driven increas biopharma invest
key driver increas larg molecul spend record high capit
market fund biotech sector recent year success key pipelin
drug immuno-oncolog io area key compon
heighten sentiment sector
figur biotech fund all-tim high
biocenturi note includ ventur follow-on ipo
improv review time fda contribut
increas pace drug launch
robust fund improv review time fda part contribut
healthi rate new drug launch drive even better
fund environ fda approv process histor bottleneck
new drug launch rise biolog recent biosimilar
made approv process complex increas resourc
agenc time approv trend improv given critic
drug candid valu shorter timelin earli develop launch
develop fda posit fact volum new drug
launch robust part due
figur drug approv healthi
figur approv time reduc last year
number biopharma activ develop pipelin
increas
number compani activ develop pipelin increas
benet redund program like
preval compar pipelin hous within
concentr number entiti increasingli role small mid cap
biotech becom like outsourc develop hub tradit pharma
seek acquir biotech program deem attract
strateg exist develop pipelin
approvalstherapeut biolog total review time nme month average total review time biolog month decemb
figur number biopharma rm activ product develop
biopharma partnerships/licens deal
howev also note number biopharma partnerships/licens
deal increas well would impli consolid
develop pipelin among grow number compani
prolifer smaller biotech compani becom incub
center research portion larg pharma gener
reli larg pharma take later stage clinic develop particularli
post-phas iib partnership deal focu earli research
preclin studi accord im licens activ among top
pharma compani deal per compani across develop stage
averag total valu per deal howev believ
improv capit fund environ reduc incent partnership
figur number partnership deal
opportun outsourcing/cro penetr
preclinicalpi-piiilaunch post-approv decemb
us biopharma industri account total spend
clinic trial accord phrma recent evaluatepharma estim
biopharma spend project increas
forecast growth lower averag part due
improv trial ecienc better use data predict analyt
also compon expect reduc pharma spend due revenu
pressur generics/biosimilar well uncertainti around price given
recent polit regulatori climat us
close biopharma estim spent develop
develop spend estim address preclin
market address clinic market
primari address market current estim cro
penetr address clinic develop spend expect
develop spend increas commensur total spend
 increas cro penetr develop budget provid
increment growth cro industri growth histor cro
engag increas everi clinic phase pharmavoic estim
clinic trial includ form anoth cro
figur address develop spend outsourc increas
ling deutsch bank estim
biopharma hope gain outsourc cro
survey world-wide clinic trial highlight key capabl
choos specic cro abil deliv high qualiti data respond
abil deliv time abil deliv within budget also
accord insight survey sponsor choos outsourc gain
access special tech improv qualiti gain oper
subject matter expertis leverag regulatori expertis tuft
survey found usag posit correl faster cycl time
improv time site ident site initi week week
averag without cro involv researchandmarket highlight
clinic phase begin trial conduct averag complet
quicker conduct sole in-hous sponsor
sponsor also primarili look knowledg best
global trial site specic project ta particularli rare/orphan
diseas limit patient popul dicult access
competit patient popul increas therapi becom
larger part biopharma develop pipelin extens
experi global wide varieti global site strong investig
relationship gener best abl compet secur site recruit
investig investig relationship critic key discern
patient interest particip trial therebi save recruit
retent cost well acceler timelin
biopharma expect ration outsourc vendor like also
though biopharma gener believ pursu vendor consolid
insight respond highlight plan increas
number work believ account expect
increas smaller/nich cro usag gap trial requir specialist
need whether ta expertis abil expect vendor
consolid thesi intact larger evidenc greater strateg
partnership see usag smaller also increas
 spend larg molecul expect increas
key driver spend growth greater emphasi larg
molecul biolog account total biopharma spend
accord isrreport project biolog continu
key driver industri spend growth
use evaluatepharma estim roch novarti merck
sano expect top big pharma spender account
total biopharma industri spend biotech compani expect
grow much faster rate tradit pharma within top
therapi market biotech revenu expect go total
rx sale top player biotech space expect
genentech roch merck complex therapi expect
becom promin orphan drug expect fastest
growth categori rise rx sale oncolog
categori expect compris total rx over-the-counter sale
novel therapi cell therapi gene therapi expect gain
signic traction estim gener cumul
larg biopharma compani compris total industri spend
accord isrreport larg molecul program current compris
spend larg small/mid size biopharma
figur industri spend composit compani type
sector consolid continu
cro industri concentr use still see
plenti fragment opportun value-accret industri
particip follow tabl summar cro deal recent
figur signic amount cro deal activ recent year
rose grow number trial heighten
complex weigh backlog convers
number activ program increas
grow number biotech increas fund number
activ program increas averag pace
activ program preclin phase investig new
drug ind applic biolog compris total submiss though
grow much quicker rate standard drug chemic entiti applic
closedacquirertargetofferttm target fundamentalsacquisit multiplesevsalesebitda ex rivermpi riverkw gtcr financiaalbani molecular riverbrain develop affair co riveragilux riverblu riverwil plcpmg riveroncotest solut plcmedimedia riverargenta rivergalapago cro cri street decemb
indic activ clinic trial landscap continu shift
figur number activ preclin program global
figur ind submiss indic biolog convert
complex trial increas
complex trial rise larg part due prolifer
biolog particular oncolog develop program program
increasingli target smaller patient popul person
biomark use creat novel therapi expand indic
key driver declin cro backlog convers trend trial take
longer initi industri estim indic trial enrol
averag patient whether
larg small specic patient popul becom dicult
recruit retain patient estim site miss enrol
target end delay due recruit issu addit
typic dropout rate patient complianc issu due
burden travel trial site
figur trial complex increas
getz trend clinic trial design complex sup simpl averag across pi-piii iqvia analyst day
present number averag per trial
oncolog key area focu pipelin key driver trial
 pipelin today compris complex diseas drive much
larg molecul formul prolifer program part driven
greater emphasi toward person medicin wherebi drug candid
target smaller specic patient popul oncolog largest
focu activ develop program
figur oncolog key area focu pipelin
phrma biopharmaceut perspect spring
immuno-oncolog io trial particularli complex
key oncolog focu contribut trial complex larg
volum immuno-oncolog io trial includ combin therapi
requir intric integr trial turn expect continu
drive strateg sponsor/cro allianc order integr plan system
process across phase particularli preclin pi trial becom
adaptive/it see clinic trial futur adapt trial adjust
trial design element real time use cumul data readout date
believ adapt trial becom promin requir cro
growthnumb distinct number procedur per studi diseas health decemb
nimbl respons real time trial chang suspect
would ideal call smaller io trial also becom increasingli
complex base newer endpoint requir investig
adequ experi conduct trial therefor cro relationship
investig prove critic
cro abil help allevi mount cost complex trial limit
keep pace rise complex key challeng
biopharma industri pressur valu proposit tuft
csdd studi found last decad rise depend
develop speed cost well success rate
improv fact case metric worsen virtual oset
complex challeng happen cost drug develop
continu escal develop cycl continu extend greater
incid delay chang order progress preclin also
seen drastic improv ind ultim reach
market argument could made complex therapi higher valu
proposit ever-escal invest necessari price make
scientic breakthrough advanc patient care would ultim
reimburs market
meaning project delay cancel caus multipl factor
given gener high custom concentr level cro meaning project
delay cancel quickli alter growth prole compani
ultim level disrupt depend size number
project impact inform readili avail caus
project-rel disrupt includ biopharma drug pipelin reevalu
repriorit sponsor project failur research phase project scope
figur revenu concentr custom
compani ling present
client concentr gener declin last decad reduc risk
note client concentr gener declin last decad
cro usag increas among sponsor busi line expans larg
 area tech/analyt cso consult
reduc client exposur risk said increas strateg partnership
case counter trend exampl case iclr
partner pzer brought top client concentr
peak iclr sinc reduc
exposur furthermor biolog pipelin recent year
believ addit longer start time qualit risk delay
cancel higher given greater complex uncertainti
underli scienc rel small molecul program
larg biopharma histor headwind cro industri
relat larg biopharma loss singl custom
materi impact near term perform futur growth prospect
acquir gener re-evalu target develop pipelin look
minim redund repriorit outright cancel project
estim custom risk somewhat lower larger cro given
higher probabl cro work acquir
target lessen risk lose custom nevertheless ration
pipelin short term disrupt custom consolid would still
cro valuat base ntm ev/ebitda current averag repres
premium vs averag premium
cro valuat base ntm price-to-earnings current averag repres
premium vs averag premium
contract research organ provid outsourc research
develop servic regulatori scientic support infrastructur
stang support life scienc industri evolv
mani decad limit clinic trial servic provid fulli outsourc
provid drug develop preclin discoveri servic clinic
often refer phase i-iii phase iv/post approv monitor
commerci therapeut regulatori clinic expertis cro
help improv cost develop improv speed clinic
trial complet
broadli speak clinic trial process broken
three overarch compon discoveri earli develop also call
preclin clinic trial phase i-iii commerci post-approv
discoveri earli develop preclin research
drug discoveri repres earliest stage research sponsor
seek identifi screen select lead molecul futur drug develop
drug discoveri activ extend anywher year convent
research practic may overlap select develop activ
uncommon trial sponsor explor drug
molecul stage develop per fda-approv drug
drug develop trial sponsor aim demonstr safeti toler
clinic ecaci select compound stage earli
develop compound test in-vitro test tube in-vivo anim
support plan on-going human clinic trial
clinic research refer studi trial done human
develop design clinic studi consid want accomplish
clinic research phase outlin
phase phase trial typic involv healthi volunt
peopl disease/condit purpos phase trial determin
molecul safeti appropri dosag consid rst time
compound test human subject phase studi look gather
preliminari inform drug interact human bodi nd
much drug bodi toler side eect
phase trial typic last sever month approxim drug
studi move onto phase ii
phase ii phase ii trial typic involv sever hundr peopl
disease/condit target purpos phase ii trial determin
treatment ecaci side eect phase clinic trial process
research administ drug group patient condit
drug seek treat studi typic larg enough show
whether drug beneci instead aim provid research
addit safeti data aect patient popul data phase
ii trial use rene research scope design phase protocol phase ii
trial typic last sever month year approxim
drug studi move onto phase
phase phase trial typic involv volunt
aect diseas condit target purpos phase
trial determin treatment ecaci monitor patient advers
reaction research design studi demonstr whether
product oer treatment benet specic popul phase trial provid
safeti data gather clinic trial process due patient
size trial durat phase studi also longest clinic trial
last year averag approxim drug
success phase studi move
commerci post-approv research/monitor phase iv
commerci commerci fda-approv drug may involv
establish patient provid awar conduct market access research
establish sale forc readi custom support program
sever thousand volunt aect disease/condit phase iv
trial conduct drug receiv fda approv primari purpos
trial studi safeti ecaci post-market safeti monitor
pleas see overview clinic trial process figur
develop phasedrug discoverypreclinicalphas iphas iiphas iiimain activitychem synthesispharmacologysafeti dosageefficaci side effectssid effect long term daysnumb activitieslead discoverypharamcolog screeningpharmacokineticsclin proof principlelarg safeti studiestarget identificationpharmacodynamicsapi productiondos rang findinglarg efficaci studiesassay developmentpharmacokineticsgmpgmp formulationlarg scale manufacturinglead optimizationtoxicokineticsformulationapi productionhit identificationacut toxicityin vivo testingsubchron toxicitymedicin chemistrygenotoxicitysardartexploratori pkpathologyexploratori toxicologymetabolismpharmacologyexampl cro servicesproduct develop strategi consultingdigit servicescontract sale cso regulatory/compli consultingadvertisingmarket entry/exit servicesprocess/it consultingpubl relationsmultichannel managementmed communicationspati engag servicesnaming/brandingmed adherenceind filingfda approvalnda submissionclin trialsdiscoveri earli developmentreproduct toxicitycarcinogenicitychron yearcentr laboratoryresearch model supplybiomarkersimmunoassaysspeci toxicityaddit genotoxicityinvestigator/sit recruitmentstudi design oper planningbioanalyt laboratorycentr laboratoryclin pharmacolog unit phase clinic clinic staffingmed writingadapt designphas iv post-marketingcommerci post-approv research/monitoringmed imagingsafeti pharmacovigilancecardiac safeti ecg lab servicespk biostatisticsclin data managementclin monitoringpati recrutimentsit regulatori start decemb
cost develop new medic increas rapidli mani would argu
trajectori unsustain
unsustain path cost drug develop grow
enorm well cost new medicin need someth
make entir process less costli ecient otherwis
continu realiz practic benet advanc scienc form new
better medicin
research tuft center studi drug develop
estim averag cost develop gain fda approv new
of-pocket cost billion time valu cost billion estim
averag cost post-approv studi test new indic formul
dose monitor patient safeti requir fda addit
million bring tuft center estim total cost billion
singl approv compound
figur average cost develop launch new drug
parexel biopharmaceut statist book tuft center studi drug develop deutsch bank
dynam outsourc decis
sponsor choos outsourc drug develop capabl
varieti reason includ access capabl found in-hous shift xed
cost variabl cost achiev greater global reach scale reason
outsourc may dier custom type sophist trial life
scienc compani small even virtual control intellectu properti
own minim asset mean need outsourc nearli everi piec
drug develop process compani larg pharmaceut
manufactur maintain research develop capabl in-
hous may choos outsourc specic compon
develop process function servic provid relationship due
resourc constraint special expertis lack requir geograph
footprint compani outsourc portion develop
work benet choos project base valu
provid also may benet economi scale will commit
outsourc certain amount work longer period time strateg
phase expens phase sponsor
expens out-of-pocket phase develop process singl
new medic phase trial fact averag spend singl phase
trial cost run next expens develop
stage phase ii trial make intuit sens consid phase trial
involv greatest number patient span longest period time
look cost develop new medic split among variou
stage process show total pre-clin clinic cost
evolv grown time
figur develop new drug
figur industri spend function phrma
develop stageaverag cost per project number compoundstot cost includ failuresdur yr time-adjust valu launch share total spend million drug discoveri decemb
figur invest clinic phase
scientic advanc enhanc understand complex diseas
enabl new treatment extend improv qualiti life
surpris environ cost innov new advanc
person medicin requir greater invest also surpris
environ sponsor look way lower develop
cost speed time market better align cost strateg prioriti
outlin spend per nda/bla new drug application/a new
biolog applic sinc note spend doubl
time frame
gener patent cli histor led cut spend major cli
next year
number
pharmaceut patent expir fact estim
billion us small molecul brand sale face loe loss exclus
industri saw anoth billion worth annual us brand sale face
loe expect billion fall
loss mani small molecul brand pharmaceut increas
need manufactur discov new therapi replac sale
medic lost exclus last decad expect
next year
recruit studi particip arguabl dicult part clinic
recruit studi particip arguabl dicult part clinic trial
process under-enrol studi wast preciou time money
also diminish scientic/statist valid studi rais ethic
question particip enrol trial stop earli
abl nish plan research studi report result
trial recruit take coordin eort trial sponsor
prescrib doctor well time money organ strategi
sponsor small patient popul may increas diculti recruit
individu must meet specic health requir enrol trial
trial may prerequisit age gender medic histori health
statu make access recruit patient dicult
ad diculti patient recruit today industri trend toward
individu medicin small patient popul becom greater realiti
medicin get individu sponsor must weigh high
cost associ risk drug develop potenti prot
success market new compound individu drug treatment
repres major challeng current model drug develop
narrow size market without reduc cost associ
bring new drug market expert expect issu continu
get wors drive cost new medic sponsor look recoup
invest develop special medic
cro industri larg fragment domin
key player
cro industri estim highli fragment
entiti global though rel full scale breadth
servic consolid space rel common though recent
among around build capabl either data analyt
quintiles/im prah/symphoni key cro function patient
recruit ppd/acurian site manag parexel/fomativ ppd/synexu
much growth concentr larg full servic player
well small/nich mid size full servic gener trail
market growth lot consolid happen
largest servic provid cro site manag studi monitor
data manag compris total industri revenu
respect figur suggest mani largest outsourc
servic gener matur extent commodit
figur industri fragment domin sever
overview cro outsourc arrang
outsourc model gener fall full servic function servic
provid hybrid two full servic one-stop shop
arrang typic includ bid specic project rfp
arrang cro provid necessari servic
complet clinic studi studi manag site monitor data
manag biostatist medic write etc nonclin work
commerci sale consult contrast arrang
cro contract provid specic function servic gener across
mani on-going project client larg pharma gener
transit model clinic area toward full servic
work nonclin meanwhil small mid size biotech tend pursu
full servic arrang outsourc full servic work tend
lumpi project-spec revis timelin cancel
impact book revenu
price arrang vari servic fall either xed price unit price
fee servic hybrid given uiditi around drug develop timelin
cancel chang order tend common xed price arrang
view riski cro gener includ contract
stipul protect cro
getz take puls strateg outsourc relationship
figur percentag servic outsourc trial
getz take puls strateg outsourc relationship
figur percentag outsourc phase
insight preclin clinic contract research survey
writingcentr site payment administrationstatist analysispati recruit retentionmed monitoringdata managementsit monitoringsit identif selectionin-housetransact full nich servic model strateg relationship integr designregulatorysubmiss preparationmed writingcentr site payment administrationstatist analysispati recruit retentionmed monitoringdata managementsit identif selectionsit iv/post-launchphas iiiphas iiphas ipreclin decemb
strateg partnership reduc competit landscap reduc
biopharma/cro strateg partnership rel common recent
year custom look ration outsourc provid secur
benet better strateg align exampl iclr fsp-type
partnership deriv revenu partnership
date sponsor/cro relationship larg transact reduc cost
improv ecienc advanc plan dedic stang share
govern share data manag control system procedur
recogn key driver trend industri studi getz found
top biopharma compani least one strateg relationship
believ model favor larger broader capabl
smaller nich therapeut expertis note arrang
necessarili improv competit posit involv
given client gener partner sever requir competit
bid within select group studi determin larg perform
qualiti dierenc transactional/strateg relationship except
strateg relationship gener higher frequenc screen failur albeit
lower frequenc protocol amend
figur exampl strateg partnership
earli report benet pharma partner gener posit
pzer eli lilli earli adopt strateg partnership
report see benet though rais question larg
benet ration outsourc realli instanc consolid
manag vendor base report run rate
cost save howev term fundament trial improv saw
reduct enrol cycl time reduct number contract
delay day report cost save data manag
monitor latter usual largest part clinic trial spend
improv patient enrol volum
partnership benet seem oset complex expens trial
strateg relationship sinc prolifer time seri metric
indic much improv biopharma compani basic face
treadmil complex expens trial studi getz found
consist methodolog among sponsor partnership given
relationship vari detail mix intern outsourc sta
across function place specic project singl cro manag
aspect function sampl studi studi author believ
creat ineci reduc eectiv partnership
author review data studi basic found
disillusion strateg relationship among sponsor specic
avoca studi determin sponsor satis felt
relationship would achiev intend outcom lead
sponsor termin relationship
meanwhil vantag studi highlight larg percentag
partnership abl achiev collabor align expect
studi also found drug enter clinic test get
approv lend credenc
notion strateg relationship ineci special patient
popul sometim mean sponsor must doubl plan enrol
period recruit meanwhil clinic phase durat
longer frequenc chang order also show
improv dierent outsourc model similar frequenc
transact strateg relationship across clinic phase
increas number sponsor still expect use strateg relationship
continu rise
overal vantag studi found engrain percept
partner meanwhil desir hedg risk among sponsor driven
ineci outsourc model use howev studi conclud
nding increas number sponsor still expect use strateg
relationship continu rise
clinic trial futur
technolog big data drive key trend cro industri
potenti increas outsourc patient centric hot topic
focu improv overal patient clinic trial experi age social
media poor experi reput eect site investig
sponsor impact futur recruit eort adher
trend potenti drive toward greater use smaller/nich outsourc
cro also tech compani would look acquir
nimbl respons player
expect greater integr real world data
make trial robust
gener expect even greater integr
real world data make trial robust predict analyt capabl
becom ever critic data set expand hope improv
site select patient recruit key rational quintiles/
im merger spate smaller size tech acquisit
recent nice insight estim improv predict futur
failur initi clinic trial could save sponsor cro
space move toward exist cro/sponsor relationship contract
discount becom less inuenti outsourc decis cro
capabl becom critic
accord tuft cro big pharma focu data expect drive
increas personnel respons manag data set electron
health record ehr insur claim social media devic trial design
light lower patient per trial trend requir novel statist skill
compens trend maintain/improv statist power trial
plan invest nextgen solut
leverag mani recent advanc tech big data artici intellig
machin learn combin im health legaci world evid
oer drive trial ecienc nextgen develop reduc
number protocol amend low/non-enrol site acceler
patient enrol far result promis
rwe uid concept gener understood analyt real world data
rwd captur outsid tradit random clinic trial rct
centuri cure act provid legisl foundat concept
accord fda data could includ electron health record ehr
claim bill activ product diseas registri patient-gener
data includ home-us set mobil devic other rwe could
use monitor safeti ecaci post-approv also support new
innov clinic trial design includ ident faster recruit
patient key hurdl remain standard dispar data
analysi privaci concern abil peer review keep unveri
gener rwd etc
rbm trend last decad goal reduc on-sit
monitor cost compris overal clinic trial cost util
focus monitor approach insight expect rbm reduc
monitor cost rbm specialti abl identifi
dene studi risk integr multi-sourc data action way
interestingli seem disconnect percept cro
sponsor around current state rbm base survey
avoca group believ capabl support
sponsor rbm satis level tech rbm risk-bas
qualiti manag studi found sponsor
optimist current state tuft survey also found dissatisfact
site manag process sponsor somewhat/
complet dissatis felt tool tech use adequ
survey found relationship among compani better tech invest
higher satisfact level
adapt trial anoth key trend receiv support
us govern fda adapt trial adjust trial design element
patient popul requir sampl size dosag etc real time use
cumul data readout date trial run manner expect reduc
develop timelin lower cost allow ecient fda review
eectiv requir decentr least increas input trial
site develop trial design well exibl util resourc
requir masteri data set also razor sharp focu quick adopt
support competit strength nich abl
provid hand support
part reason patient adher low due diculti
reach trial site virtual trial aim connect patient trial via telemedicin
platform mobil wearabl tech expect critic featur enabl
improv monitor commun data collect recruit
phase mobil app expect use promot trial prescreen
patient cloud-bas system use expect grow technolog enabl
eas integr dispar data set
sell product servic
custom
initi buy rate
buy rate reect view compani sucient cross-sel
opportun across busi enabl sustain high single-digit organ
expand leverag core strength model safeti assess
broader rang servic
client use discoveri safeti assess servic
number compani hope increas time think
compani domin posit research model nearli share safeti
assess servic share provid right opportun
much bigger player broader fragment market discoveri servic
bioanalysi time share discoveri bioanalysi servic perhap
mid-singl digit today morev think fundament outsourc
discoveri work improv boost emerg small biotech
compani mani virtual minim intern infrastructur
cross-sel opportun provid ampl opportun organ growth also
see rich runway inorgan growth opportun
core research model servic rm busi face structur
challeng seen sign stabil evidenc organ
sale growth rst month see acceler
driven recent larg servic contract win manufactur support
front row seat long-term penetr stori rapid microbi detect
trend provid double-digit growth rate year come
forecast ratio
price dec
valuat risk
price target reect
enterpris valu use project level
debt cash
discount contract research
believ appropri reect
structur pressur rm segment
downsid risk price target includ
limit weaken market
demand product servic
specic contract cancel
expect biopharma
price target reect enterpris valu use project level
debt cash ebitda ex-opt multipl
discount contract research organ cro peer group median
believ appropri reect structur pressur rm segment
downsid risk price target includ limit weaken
market demand product servic gener reduc outsourc
demand specic contract cancel lower expect biopharma
seek drive better dsa cross sell client
long term believ premis greater penetr
discovery/bioanalysi market estim current hold
combin share market believ market oer substanti
opportun increas share consolid believ strongli
posit secur much larger piec market coupl robust
growth safeti assess sa market domin player
believ increas discoveri penetr enabl dsa segment
sustain grow high singl digit compani reorgan dsa
segment eectiv drive current new safeti assess client
depth scientic expertis one key pitch greater discoveri outsourc
categorydb viewcommentsupsid numbersstreet alreadi model hsd sale growth margin expansionupsid sentimenton consensu buycapit allocationplenti opportun appetit value-accret atargetless strateg valu preclin larg multipl expansiontrad ebitda discount peer group vs histor parityratingbuymor favor decemb
believ therapeut technic expertis build
acquisit particip discoveri program enabl
encourag greater outsourc pharma specic believ outsourc
discoveri provid like industri aspect discoveri process
certain part biopharma intermitt consist
therebi help scale process sponsor
chang client base amen outsourc
strength recent biotech fund environ seen emerg
small mid size biopharma estim
rm compris greater percentag
spend decad ago mani rm virtual mean outsid
ownership intellectu properti outsourc mani key function
includ mani case discoveri develop on-going trend give
us convict increas discoveri outsourc go forward
fragment natur discoveri market also present robust inorgan growth
given highli fragment natur earli stage cro market believ
inorgan growth opportun remain healthi continu
deploy capit toward acquisit build dsa segment recent
acquir mpi research manag strongli favor continu build
dsa segment expect year robust
deal activ compani
charl river largest earli stage-focus cro major
activ discoveri preclin stage drug develop
addit compani provid set manufactur support servic post
drug launch undergon sever busi transform sinc
found anim model busi maintain continu
compani work drug approv fda compani
report oper three busi segment research model servic
revenu discoveri safeti assess
revenu manufactur support revenu
figur revenu segment
figur revenu geographi
research model servic rm revenu
global leader breed suppli rodent anim model use
drug research discoveri safeti assess sa well support
servic compani dierent varieti strain rat mice
rang standard model span immunodeci human model
genet engin model gem use research model earli drug
research develop gener regulatori requir prior
initi clinic in-human trial
figur domin player research model servic
segment subdivid
research model small larg rm segment revenu
research model servic safeti assess decemb
largest supplier purpose-br rat mice use biopharma
compani govern agenc hospit academ institut
model includ outbr inbr spontan mutant hybrid
research model servic rm segment revenu
genet engin model servic breed maintain
well advis biomed research client ecient creat
anim model also phenotyp platform design
character creat model compani maintain team project
manag assist client technic expertis varieti gem need
coloni develop assist reproduct
insourc solut provid outsourc stang manag
servic earli stage research oper addit lab support
gov commerci
research anim diagnost servic rad crl refer diagnost
lab provid anim model health monitor analysi client
discoveri safeti assess dsa revenu
segment provid outsourc servic drug discoveri research
develop well safeti test drug chemic medic devic
dsa segment largest custom rm segment compris
rm unit volum
discoveri servic dsa segment revenu
earli discoveri predomin focu provid vitro biolog
medicin chemistri research lab client facil part
in-sourc solut servic client includ target discoveri
valid hit ident test drug absorpt distribut
bodi metabol excret adm compani also provid genom
discoveri servic servic use ident screen
select lead compound earli stage discoveri work
complement client intern capabl order speed discoveri
process reduc cost also oer vitro vivo assay use
streamlin optim lead drug candid select
safeti assess sa dsa segment revenu
util scientist compani provid wide rang safeti studi
perform preclin phase bioanalysi drug metabol
pharmacokinet safeti pharmacolog toxicolog compani also oer
patholog servic perform in-hous veterinari anatom clinic
figur top player safeti assess market
manufactur support revenu
segment focus outsid pre-clin drug develop
phase provid rang servic support client manufactur
oper includ qualiti safeti assess biolog test
microbi solut segment revenu
compris endosaf celsi accugenix busi oer
convent rapid qualiti control test steril non-steril biopharma
consum product endosaf devic cartridg use test
steril medic devic biopharmaceut endotoxin contamin
celsi system use test microbi contamin
steril complementari two test system accugenix lab network
use identifi specic type microbi contamin detect
manufactur process
maintain global network lab provid outsourc test servic
biolog compound ensur consist stabil manufactur
immunochemistri microbiolog cell biolog vivo studi
compani suppli specic pathogen-fre spf chicken egg chicken
whose embryo use bio-reactor manufactur live virus
develop vaccin veterinari human market compani also
lab provid qualiti control test client poultri well
manufactur poultry-spec diagnost antigen vaccin
period end incom expens expens incom incom non-control incom share share ep dilut sale excl acquir intang cash flowoperar cash cash revenu
period end equival short-term receiv current equip relationship intang asset sharehold equitycurr matur lt current non-controlling liabil sharehold equiti minor decemb
ride wave less self-
initi hold rate
hold rate iclr reect view recent perform
impress compani slower deploy capit
best day margin expans behind
price dec
perform admir ex-pzer stock alreadi
exclud pzer believ sale growth rate double-digit
month vs total organ sale growth book/bil ratio
compar favor peer sale pzer expect go
forward organ revenu growth acceler said street alreadi
model sale growth stock appear alreadi
reward recent perform moreov see degre
market penetr expans iclr peer
balanc sheet deploy slow
iclr much slower deploy balanc sheet
compani current sport net cash posit activ look
market multipl challeng
margin expans rapid asymptot
iclr expand oper margin mid-singl digit gross revenu
mid-teen forecast believ margin expans go
forward dicult achiev particularli due servic mix
inat compani highlight opportun drive ecienc routin
task necessarili skeptic annual ebit margin expans
target much see littl upsid target
forecast ratio
valuat risk price target
iclr reect enterpris valu use
project level debt cash
ebitda ex-opt
multipl discount contract
median believ appropri
reect concern limit margin
expans opportun downsid risk
price target includ limit
weaken biotech capit market
fund slower expect outsourc
higher typic contract cancel
rate lower expect biopharma
 spend growth upsid risk
price target includ better expect
revenu growth margin expans
execut value-accret
price target iclr reect enterpris valu use project level
debt cash ebitda ex-opt multipl
discount contract research organ cro peer group median
believ appropri reect view limit rel growth upsid
downsid risk price target includ limit weaken
biotech capit market fund slower expect outsourc higher
typic contract cancel rate lower expect biopharma
spend growth upsid risk price target includ better expect
revenu growth margin expans lead higher ep growth sizeabl
iclr revenu acceler notwithstand need convinc
could achiev peer better growth rate cycl challeng view
includ over-exposur pzer still repres sale
expect compris sale go forward slower balanc sheet
deploy lesser opportun margin expans vs recent past
unclear iclr competit disadvantag bid process vs peer
proprietari data asset iclr focus data partnership
pzer good custom growth liabil
categorydb viewcommentsupsid numbersstreet alreadi assum revenu accelerationupsid sentimentbuy hold/sel rate allocationnet cash balanc histor slow deploy balanc sheettargetwel manag pure play consolid industrymultipl expansiontrad pariti group ebitdaratingholdmor favor decemb
iclr much less exposur pzer use sale today
vs year ago exposur still repres rel drag
compani overal growth rate iclr sale pzer drop
balanc sheet deploy slow
iclr balanc sheet conserv greater net cash
posit stand contrast mani peer lever
ebitda greater follow strateg acquisit valuat
challeng iclr certainli disagre price disciplin
wonder conserv strategi challeng rel growth
compani market deal perhap recent stock market volatil
shake loos target
wage inat shift could pressur margin
broader industri shift function outsourc pose structur margin
pressur iclr estim iclr busi carri
gross margin rang vs corpor
remain strateg prioriti iclr particularli becom
prefer outsourc arrang larg pharma client moreov
increas import small biotech broader cro market carri
neg mix larg pharma busi gener higher margin
busi smaller biotech compani also recent began highlight
wage inat certain job function headwind
iclr manag maintain oper expens rel last four
year stem impact gross margin eros earn compani
highlight ecient manag routin task driven robot process
autom next leg opex control necessarili skeptic
compani nd ecienc much see littl upsid
captiv data strategi earli day iclr potenti disadvantag
captiv data strategi iclr peer may earli inning
see risk iclr could competit disadvantag futur
compani focus data partnership vs data ownership
icon iclr dublin-bas cro found provid
key outsourc support biopharma medic devic industri one
major player scale iclr abl provid clinic trial support
major therapeut area either full servic solut specic function
compani capabl across earli develop clinic trial
phase acquisit mapi iclr becom second largest
late phase provid global compani locat countri
employe deriv revenu us ireland
rest europ row
iclr compet reduc develop timelin better trial planning/
design site id/pati access ecient trial execut earli id drug
ecaci servic span across product life-cycle includ earli phase
lab servic site patient recruit clinic research function servic
consult commerci outcom major revenu
deriv clinic research follow resourc
lab servic compani histor high
revenu concentr pzer gradual come
iclr divers eort well
larg project cancel bococizumab late
figur net servic revenu geographi
figur net servic revenu client
figur backlog book-to-bil trend
data strategi focus partnership ownership
iclr data strategi current focus data ownership analyt
partner data provid site ident compani
combin one search platform partner independ provid
trinetx real time scenario model feasibl studi plan
real world data iclr partner compani like ichom saama
practic fusion compani reli icon informat hub
analyt also partner aggreg analyz patient data
wearabl tech
iclr focus enhanc site network
client backlogttm book bill decemb
key pillar iclr strategi build captiv site network
iclr believ improv patient access recruit rate
compani acquir pmg research integr clinic research site network
compris site across us pmg brought trial particip data
proprietari databas well electron health record ehr data million
activ patient partnership health system physician sinc
iclr expand site network may partnership
dupag medic pmg take control dupag research site
across chicago area iclr comment current activ
project use in-hous site network new project come
on-line run network iclr current site network primarili us-
focus compani plan expand footprint europ asia
capabl adjac area
acquisit iclr enter medic devic trial
outsourc space med-tech industri adopt trial outsourc
readili biopharma continu rel small part iclr busi
acquisit clinicalrm compani enter militari
research project rel small part much larger govern
market iclr see opportun expand nih side much
period end incom expens share share ep revenu net revenu margin gross servic gross gross margin gross servic cash flowoperar cash cash
period end cash equival st receiv current asset asset sharehold equityst matur lt current liabil sharehold equiti minor decemb
expand direct
initi buy
buy rate reect view compani eort leverag
core strength inform servic technolog servic clinic real-
world research lead acceler revenu growth share gain time
price dec
synergi legaci im quintil busi start
materi sale acceler
key strategi quintiles/im merger improv cro
oer leverag im data creat smarter cro compani
focus synthes vast amount anonym patient data
supplier nextgen oer drive faster ecient site select
recruit start execut begun see synergi
materi book/bil rate busi past
quarter believ book translat sale acceler
begin
earli day penetr analyt tam
believ compani signic runway leverag technolog
data asset penetr technolog analyt total address
market well market real world evid rwe commerci
softwar suit highlight orchestr custom engag oce
custom relationship manag tool gener impress
earli win clearli disturb competit environ rwe oer
estimate mid-singl digit portion sale provid growth lever given secular trend
healthcar industri toward valu outcom base medicin
forecast ratio
valuat risk
price target reect
enterpris valu use project level
debt cash
premium contract research
believ appropri reect
multipl avenu growth acceler
downsid risk price target
includ limit weaken
biotech capit market fund
slower expect outsourc higher
typic contract cancel rate
lower expect biopharma
price target reect enterpris valu use project level
debt cash ebitda ex-opt multipl
premium contract research organ cro peer group median
believ appropri reect multipl avenu growth acceler
downsid risk price target includ limit weaken
biotech capit market fund slower expect outsourc higher
typic contract cancel rate lower expect biopharma
debat drive synergi expand asset
base acceler growth
key strategi quintiles/im merger improv cro
commerci oer leverag im data creat smarter cro
compani focus synthes vast amount anonym patient
data supplier nextgen oer drive faster
ecient site select recruit start execut also aim
leverag data strengthen posit world evid rwe two-
way connect clinic trial commerci activ believ
data analyt develop much cro industri
categorydb viewcommentsupsid numbersstreet model acceler businessupsid sentimentbuy outnumb hold opportun re-rat execut technology/data-en strategycapit allocationexpect tuck-in buyback annuallytargetscal uniqu busi mix challeng suitorsmultipl expansionopportun re-rat execut technology/data-en strategyratingbuymor favor decemb
see provid suffici differenti offer drive
share gain cro busi
nextgen drive growth exit
highlight current growth rate base compani continu
execut primarili pre-merg book particularli pressur
believ next leg growth come on-going robust
nextgen award base analysi nextgen book activ revenu
convers assumpt expect meaning growth contribut
exit align commun
increment solut growth cro industri baselin compani
estim near-term nextgen trial activ
nish almost cumul nextgen award post-merg
total net award sinc merger compani base roughli
half recent rfp bid nextgen capabl highlight
win rate date vs standard bid emerg biopharma
key custom group nextgen compris much recent
transcript press releas
 nextgen awardscumul net award decemb
figur expect book nextgen convert revenu
posit healthcar data unriv leverag sh larg
believ signic runway leverag vast anonym
patient data gain larger foothold broader tech analyt
market notabl recent foray includ real world evid rwe
solut newest oer orchestr custom engag oce
rwe current busi compani grow doubl digit
believ rwe provid solid growth lever given secular trend
healthcar industri toward valu outcom base medicin requir
real time divers data post-commerci phase iv feedback loop
measur treatment eectiv exampl certain part europ
brand drug maintain price premium market manufactur
must provid proof better outcom govern year launch
believ data trillion transact annual highli valuabl
defens asset well posit secur larg part yet
compani launch oce secur major contract
roch mainli posit servic given integr
real time data fast-grow salesforc believ
make highli competit oer pharma market
home strong incumb veeva switch
cost high gener posit abil gain share
gain condenc growth trajectori next month
base rate type major pharma contract secur note
roch win repres abil leverag inform
data custom base believ span essenti healthcar
landscap cross sell addit solut believ bode well
futur revenu synergi opportun includ cro busi
meantim new go-to-market strategi drive growth
medium term believ current strategi bid
emerg biopharma contract legaci quintil realli activ
potenti acceler revenu growth target mid singl digit
particularli true time rfp grow teens-rat
post merger book recogn revenu decemb
new win driven ttm book-to-bil emerg biopharma
contract gener smaller averag broader landscap
opportun categori biotech fund continu reach histor
level also highlight potenti win larg pharma
contract slate renew could acceler
figur secur larger slice book pie
iqvia provid health inform analyt contract research
servic compani emerg merger data analyt
rm im health largest global full servic cro quintil
data informat side boast one largest comprehens
patient dataset world consist greater million record
health record ehr social media appli proprietari organ
analyt data sell varieti end market cro
side compani provid servic across discoveri develop cycl
albeit primari focu phase ii-iv clinic trial well launch post-
launch servic oper countri employ
peopl
report three broad segment technolog analyt solut
solut contract sale medic solut
qtrli net book excl reimburs iqvcovancesynhprahiclr decemb
figur revenu segment
figur revenu geographi
technolog analyt solut previous commerci solut
segment primarili consist im health legaci inform
servic busi roughli segment revenu
servic fastest grow sub-seg includ cloud-bas
softwar clinic commerci support client provid
softwar servic saa form also oer real world insight
assist track aspect therapeut econom eectiv
newli launch drug compris proprietari analyt patient-level data
integr varieti dierent sourc ehr prescript
medic claim compon sub-seg workow analyt
consult servic assist client commerci oper eg portfolio
brand strategi well drug develop process late
launch orchestr custom engag oce saa softwar
dub platform platform suit commerci function
applic alreadi integr enabl improv coordin
streamlin client commerci activ
inform larg sub-seg includ nation sub-nat
refer inform oer measur perform metric
drug prescript trend promot activ across sever market
channel refer databas consist data point million
healthcar profession use client launch/post-launch strategi
trend underli growth segment includ prolifer data sourc
increas fragment technolog addit advanc
person medicin drive specialti product market
turn make target physician access critic believ better
ecient data analyt key evolv landscap addit
focu value-bas system rise drug develop spend key
driver toward rwe-bas solut
 revenu
segment primarili legaci quintil cro busi includ
project manag clinic trial monitor studi design patient
etc strateg plan design regulatori aair etc also includ
within segment jv squar oer
clinic trial genom bioanalyt lab servic
one key rational im health/quintil merger drive
synergist use im data analyt platform improv drug
develop process part cro busi oer emerg
nextgen solut use big data artici intelligence/machin
learn predict analyt improv optim variou aspect drug
figur area improv develop life-cycle
trend underli cro market growth includ underli biopharma
 spend growth increas outsourc outsourc driven
varieti dierent factor mainli cost control measur client
also proven capabl speed develop time line
ultim improv drug candid irr across oper area also
drive greater outsourc earli data nextgen oer indic signic
improv key metric critic biopharma client speed site
select start patient recruit result look promis
expect get better sens time sampl trial use oer
servic revenu
segment consist post-launch servic though healthcar
provid engag servic act contract sale organ
cso provid outsourc sale team market access profession
biopharma medic devic compani patient engag servic
provid nurs educ engag directli patient educ
medic adher purpos final medic aair servic
design consult biopharma compani transit clinic trial
busi face growth headwind sinc manag
attribut cyclic natur cso industri follow strateg
review compani reorgan busi around local/region
model improv custom respons reduc cost
period end incom expens expens earn loss incom excl incom non-control incom share share ep dilut excl incl stock-bas sale growth margin servic margin gross restat excl acquir intang cash flowoperar cash cash adj
period end equival short-term current equip intang asset unconsolid sharehold equitycurr matur lt payabl current liabil sharehold equiti minor decemb
